AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11239634 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated patch plus placebo tablet
Number of subjects: 84
Study 11239634 — intervention group
Group type: EXPERIMENTAL
Intervention: Unheated patch plus ibuprofen
Number of subjects: 84
Study 11239634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination heated patch plus ibuprofen
Number of subjects: 84
Study 11239634 — intervention group
Group type: COMPARATOR
Intervention: Unheated patch plus placebo group
Number of subjects: 84
Study 11239634 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated patch plus ibuprofen
Number of subjects: 84
Study 31521161 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-based psychomotor/psychosocial stimulation during hospital stay and at home for 6 months after discharge
Number of subjects: 339
Study 31521161 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care and nutritional treatment
Number of subjects: 339
Study 30006305 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-T lymphocyte globulin (ATLG)
Number of subjects: 254
Study 30006305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 26608054 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral transverse process-pedicle PKP
Number of subjects: 56
Study 26608054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral PKP
Number of subjects: 56
Study 23942869 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 409
Study 23942869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 22227341 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography analysis
Number of subjects: 2136
Study 20832819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrhythmia monitoring
Number of subjects: 1816
Study 20832819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia monitoring
Number of subjects: 1816
Study 20832819 — intervention group
Group type: EXPERIMENTAL
Intervention: QT interval monitoring
Number of subjects: 1816
Study 17369807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide supplement (E)
Number of subjects: 30
Study 17369807 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 17369807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 30
Study 15903284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist transition coordinator
Number of subjects: 110
Study 15903284 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital discharge process
Number of subjects: 110
Study 11989986 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced community management (ECM)
Number of subjects: 193
Study 11989986 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 193
Study 9796354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide infusion cholescintigraphy
Number of subjects: 26
Study 7705012 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg tid
Number of subjects: 263
Study 7705012 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 1000 mg tid for RTIs and 500 mg tid for UTIs
Number of subjects: 263
Study 2533786 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine + multiple doses of HBIG (Group I)
Number of subjects: 235
Study 2533786 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine + single dose of HBIG (Group II)
Number of subjects: 235
Study 2533786 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine only (Group III)
Number of subjects: 235
Study 2533786 — intervention group
Group type: COMPARATOR
Intervention: Heat-inactivated hepatitis B vaccine only
Number of subjects: 235
Study 2533786 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of HBIG
Number of subjects: 235
Study 2533786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of HBIG
Number of subjects: 235
Study 2533786 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 235
Study 405902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine in Adsorbobase
Number of subjects: 0
Study 405902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine in 0.5% hydroxypropyl-methylcellulose solution
Number of subjects: 0
Study 405902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (both formulations)
Number of subjects: 0
Study 31590286 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Ketogenic (VLCK) diet
Number of subjects: 79
Study 31590286 — intervention group
Group type: COMPARATOR
Intervention: Low-Calorie (LC) diet
Number of subjects: 79
Study 31590286 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 79
Study 28697789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular or intra-arterial injection of 40 ml BM-MNC concentrate
Number of subjects: 50
Study 25483023 — intervention group
Group type: EXPERIMENTAL
Intervention: IDet+IAsp
Number of subjects: 403
Study 25483023 — intervention group
Group type: COMPARATOR
Intervention: BIAsp1-2-3
Number of subjects: 403
Study 23665335 — intervention group
Group type: EXPERIMENTAL
Intervention: HERA (Health Evaluation and Referral Assistant)
Number of subjects: 1006
Study 23665335 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 1006
Study 21989078 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1 g, twice daily
Number of subjects: 159
Study 18177701 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (CLF)
Number of subjects: 50
Study 18177701 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia 21 (PAN)
Number of subjects: 50
Study 18177701 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II (VAR)
Number of subjects: 50
Study 18177701 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (UNI)
Number of subjects: 50
Study 18177701 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental GC self‐adhesive cement (EGC)
Number of subjects: 50
Study 18177701 — intervention group
Group type: COMPARATOR
Intervention: Panavia 21 (PAN), Clearfil Esthetic Cement (CLF), Variolink II (VAR)
Number of subjects: 50
Study 18177701 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem (UNI), Experimental GC self‐adhesive cement (EGC)
Number of subjects: 50
Study 16467423 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal eye fields (FEFs) activity during response selection
Number of subjects: 0
Study 16467423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraparietal sulcus (IPS) activity during response selection
Number of subjects: 0
Study 14586213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 25 mug/m(2) as a 1-h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I)
Number of subjects: 70
Study 14586213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 120 mug/m(2) as a 72-h continuous infusion every 2 weeks (Regimen II)
Number of subjects: 70
Study 10587284 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day
Number of subjects: 63
Study 10587284 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg/day
Number of subjects: 63
Study 10587284 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day + Lithium
Number of subjects: 63
Study 10587284 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg/day + Lorazepam 4 mg/day
Number of subjects: 63
Study 10587284 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day + Lorazepam 4 mg/day
Number of subjects: 63
Study 10587284 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 mg/day + Placebo
Number of subjects: 63
Study 8727681 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated traumatic pictorial stimuli (combat related pictures)
Number of subjects: 40
Study 8727681 — intervention group
Group type: COMPARATOR
Intervention: Target stimuli (domestic animal pictures)
Number of subjects: 40
Study 1659980 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg intravenously before chemotherapy, with up to two further doses daily of 40 micrograms/kg if necessary)
Number of subjects: 115
Study 1659980 — intervention group
Group type: COMPARATOR
Intervention: Alizapride plus dexamethasone (4 mg/kg alizapride and 8 mg/kg dexamethasone before chemotherapy, repeated if necessary after 4 and 8 hours up to two additional doses)
Number of subjects: 115
Study 6119558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1943
Study 6119558 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1943
Study 30968327 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvre (RM) with positive end-expiratory pressure (PEEP)
Number of subjects: 19
Study 30968327 — intervention group
Group type: COMPARATOR
Intervention: Control group (without RM)
Number of subjects: 19
Study 31806191 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 1200
Study 31806191 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 1200
Study 28752157 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealants
Number of subjects: 405
Study 28752157 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealants
Number of subjects: 405
Study 28752157 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer ART sealants with heat application
Number of subjects: 405
Study 28752157 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer ART sealants without heat application
Number of subjects: 405
Study 26340571 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention Training for alcohol problems (16 hours duration)
Number of subjects: 120
Study 26340571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 120
Study 23179254 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturography-assisted vestibular rehabilitation protocol (30 min a week) combined with home-based exercise program (Group A)
Number of subjects: 28
Study 23179254 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program alone (Group B)
Number of subjects: 28
Study 20816833 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol/beclomethasone 12/200 μg Modulite
Number of subjects: 28
Study 20816833 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol/budesonide 9/320 μg Turbuhaler
Number of subjects: 28
Study 20816833 — intervention group
Group type: COMPARATOR
Intervention: formoterol alone
Number of subjects: 28
Study 18204873 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual molecular weight (DMW; 580-780 kDa + 1.2 to 2.0 million Da)
Number of subjects: 200
Study 18204873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight (LMW; 500-730 kDa)
Number of subjects: 200
Study 18204873 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight (HMW; 6 million Da)
Number of subjects: 200
Study 18204873 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200
Study 16416322 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance program (12 weeks, 3 times per week, 20 min per session) before soccer training (TxB group)
Number of subjects: 39
Study 16416322 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance program (12 weeks, 3 times per week, 20 min per session) after soccer training (TxA group)
Number of subjects: 39
Study 16416322 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 39
Study 12838857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemotherapy and radiotherapy (A group)
Number of subjects: 87
Study 12838857 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and chemotherapy (B group)
Number of subjects: 87
Study 12838857 — intervention group
Group type: COMPARATOR
Intervention: Simple radiotherapy (C group)
Number of subjects: 87
Study 10849191 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg/day plus dipyridamole 75 mg/day
Number of subjects: 30
Study 10849191 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day plus placebo
Number of subjects: 30
Study 9020945 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg IV)
Number of subjects: 20
Study 9020945 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus methylprednisolone (250 mg IV)
Number of subjects: 20
Study 7937272 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized enteral formula (supplemental arginine, linolenic acid, beta-carotene, hydrolyzed protein for up to 10 days)
Number of subjects: 41
Study 7937272 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized enteral formula
Number of subjects: 41
Study 7937272 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 41
Study 3335879 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Consistency Analysis (ICA)
Number of subjects: 0
Study 29302875 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacon sham feeding
Number of subjects: 122
Study 29302875 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 122
Study 27504014 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month, culturally tailored, U.S. Diabetes Prevention Program-based lifestyle curriculum plus stepwise addition of metformin (500 mg, twice daily)
Number of subjects: 578
Study 27504014 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle advice (control)
Number of subjects: 578
Study 25616353 — intervention group
Group type: EXPERIMENTAL
Intervention: study-quiz group
Number of subjects: 96
Study 25616353 — intervention group
Group type: COMPARATOR
Intervention: quiz group
Number of subjects: 96
Study 22801006 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation training to endorse positive interpretations of mildly negative and positive social events
Number of subjects: 153
Study 22801006 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 153
Study 22801006 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation training
Number of subjects: 153
Study 20973984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-completion incentive (book token)
Number of subjects: 591
Study 20973984 — intervention group
Group type: COMPARATOR
Intervention: Post-completion incentive (promise of a book token)
Number of subjects: 591
Study 20973984 — intervention group
Group type: COMPARATOR
Intervention: No incentive (nothing at all)
Number of subjects: 591
Study 17465700 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (20 mg/day) for 12 weeks
Number of subjects: 29
Study 17465700 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin treatment)
Number of subjects: 29
Study 17465700 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (20 mg/day)
Number of subjects: 29
Study 16810279 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 100
Study 16810279 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 100
Study 11926936 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential crisis program
Number of subjects: 119
Study 11926936 — intervention group
Group type: COMPARATOR
Intervention: General hospital psychiatric unit
Number of subjects: 119
Study 11926936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 119
Study 9476862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium 4-phenylbutyrate (Buphenyl) 19 grams p.o. divided t.i.d. for 1 week
Number of subjects: 18
Study 9476862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7542142 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant preoperative radiotherapy and operation
Number of subjects: 284
Study 7542142 — intervention group
Group type: COMPARATOR
Intervention: Surgical operation alone
Number of subjects: 284
Study 7542142 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant preoperative radiotherapy
Number of subjects: 284
Study 2197911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (600 mg by inhalation using a Respirgard II nebulizer)
Number of subjects: 45
Study 2197911 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pentamidine (3 mg/kg body weight administered once daily for 2 to 3 weeks)
Number of subjects: 45
Study 2197911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 45
Study 2197911 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pentamidine
Number of subjects: 45
Study 265082 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical painting with potassium fluoride solution containing Al-, Fe-, and Mn-ions
Number of subjects: 0
Study 265082 — intervention group
Group type: COMPARATOR
Intervention: Topical painting with 0.2% NaF-solution
Number of subjects: 0
Study 7044620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen/gestagen alone or in combination with 1,25(OH)2D3
Number of subjects: 74
Study 7044620 — intervention group
Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 74
Study 7044620 — intervention group
Group type: COMPARATOR
Intervention: 1,25(OH)2D3
Number of subjects: 74
Study 30683164 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning‐Centered Grief Therapy (MCGT)
Number of subjects: 11
Study 29394367 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic falciparum malaria patients on Day 0 (D0)
Number of subjects: 109
Study 29394367 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic falciparum malaria patients in recrudescent phase (Drec)
Number of subjects: 109
Study 29394367 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic Plasmodium vivax carriers
Number of subjects: 109
Study 29394367 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic falciparum carriers
Number of subjects: 109
Study 27072880 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 54
Study 27072880 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 54
Study 25223266 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent subunit vaccine (aTIV)
Number of subjects: 6078
Study 25223266 — intervention group
Group type: COMPARATOR
Intervention: TIV-1 (non-adjuvanted version of aTIV)
Number of subjects: 6078
Study 25223266 — intervention group
Group type: COMPARATOR
Intervention: TIV-2 (split virion vaccine)
Number of subjects: 6078
Study 25223266 — intervention group
Group type: EXPERIMENTAL
Intervention: All three vaccines (aTIV, TIV-1, TIV-2)
Number of subjects: 6078
Study 22421470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 47
Study 22421470 — intervention group
Group type: COMPARATOR
Intervention: Tramadol chlorhydrate 100 mg
Number of subjects: 47
Study 19079943 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA (2 g)
Number of subjects: 8
Study 19079943 — intervention group
Group type: EXPERIMENTAL
Intervention: ETO (320 mg)
Number of subjects: 8
Study 19079943 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 8
Study 17882397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Blood Glucose (MBG)
Number of subjects: 0
Study 17882397 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose Variability (SD of blood glucose)
Number of subjects: 0
Study 17882397 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 0
Study 15179192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic cisplatin at 100 mg/m
Number of subjects: 19
Study 15179192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic cisplatin at 125 mg/m
Number of subjects: 19
Study 15179192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus PVS
Number of subjects: 19
Study 15179192 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 19
Study 12408517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distension at 10 mmHg
Number of subjects: 12
Study 12408517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distension at 12 mmHg
Number of subjects: 12
Study 12408517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distension at 14 mmHg
Number of subjects: 12
Study 12408517 — intervention group
Group type: EXPERIMENTAL
Intervention: First 15-min period of distension
Number of subjects: 12
Study 12408517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric pressure
Number of subjects: 12
Study 12408517 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall tension
Number of subjects: 12
Study 9527112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 59
Study 9527112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 7615781 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beta 2 agonist alone
Number of subjects: 18
Study 7615781 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta 2 agonist with inhaled corticosteroids
Number of subjects: 18
Study 2375304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-based diets with milk
Number of subjects: 8
Study 2375304 — intervention group
Group type: COMPARATOR
Intervention: Cereal-based diets without milk
Number of subjects: 8
Study 319724 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 9
Study 319724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31162031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (5 x 500 mg until month 18)
Number of subjects: 0
Study 31162031 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg per day, gradually decreased between month 12 and 22)
Number of subjects: 0
Study 31162031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 28454498 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg (once daily)
Number of subjects: 144
Study 28454498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 25682524 — intervention group
Group type: EXPERIMENTAL
Intervention: RIME intervention (three sessions)
Number of subjects: 28